Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
DR. REDDY'S LABORATORIES LIMITED currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units, suggesting that the company's current patenting activity touches on different specialized areas of pharmaceutical science. The prosecution involves 2 distinct examiners, meaning that each pending matter is being handled by a different official. This structure indicates a diverse but small-scale engagement with the patent office at this time.
MEAH, MOHAMMAD Y is the busiest examiner for the company, responsible for 1 pending office action. With 2 distinct examiners each handling one of the 2 pending actions, the company's prosecution efforts are not concentrated under a single individual. For the practitioner, this means developing distinct strategies for two different examiners across 2 distinct art units. The profile indicates that each of the 2 pending office actions requires a unique approach to satisfy different examiner standards. This distribution across 2 distinct art units ensures that the company's pharmaceutical filings are being reviewed by specialists in different technical niches.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAZARGANI, ARYA AHMADI | 1 | 62.5% | +31.3% |
| DRISCOLL, MAUREEN VARINA | 1 | 64.9% | +41.8% |
| LANDSMAN, ROBERT S | 1 | 81.4% | +13.0% |
| VAN DRUFF, SYDNEY | 1 | 55.3% | +32.0% |
| GURLEY, JAMI MICHELLE | 1 | 54.8% | +14.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681162 | Method To Purify An Antibody Composition Using Cation Exchange Chromatography | LANDSMAN, ROBERT S | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19049310 | LIQUID INJECTABLE COMPOSITIONS OF LURBINECTEDIN | BAZARGANI, ARYA AHMADI | — |
| 18685082 | A PROCESS TO PRODUCE A PHARMACEUTICAL COMPOSITION | DRISCOLL, MAUREEN VARINA | — |
| 18291909 | Method To Control High Molecular Weight Aggregates In An Antibody Composition | VAN DRUFF, SYDNEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19049310 | LIQUID INJECTABLE COMPOSITIONS OF LURBINECTEDIN | BAZARGANI, ARYA AHMADI | — |
| 18685082 | A PROCESS TO PRODUCE A PHARMACEUTICAL COMPOSITION | DRISCOLL, MAUREEN VARINA | — |
| 18681162 | Method To Purify An Antibody Composition Using Cation Exchange Chromatography | LANDSMAN, ROBERT S | — |
| 18291909 | Method To Control High Molecular Weight Aggregates In An Antibody Composition | VAN DRUFF, SYDNEY | — |
| 18038282 | STABLE THERAPEUTIC PROTEIN FORMULATION AND METHODS OF MAKING THE SAME | GURLEY, JAMI MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1647 | 2 |
| 1615 | 1 |
| 1644 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19049310 | LIQUID INJECTABLE COMPOSITIONS OF LURBINECTEDIN | BAZARGANI, ARYA AHMADI | 1615 | §103§112 | Non-Final OA | — | Pending | Feb 10, 2025 |
| 18685082 | A PROCESS TO PRODUCE A PHARMACEUTICAL COMPOSITION | DRISCOLL, MAUREEN VARINA | 1644 | §103§112 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18681162 | Method To Purify An Antibody Composition Using Cation Exchange Chromatography | LANDSMAN, ROBERT S | 1647 | §102§112DP | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18291909 | Method To Control High Molecular Weight Aggregates In An Antibody Composition | VAN DRUFF, SYDNEY | 1643 | §102§103 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18038282 | STABLE THERAPEUTIC PROTEIN FORMULATION AND METHODS OF MAKING THE SAME | GURLEY, JAMI MICHELLE | 1647 | §103 | Non-Final OA | — | Pending | May 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDR. REDDY'S LABORATORIES LIMITED has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Arya Ahmadi Bazargani has the most, with 1 of DR. REDDY'S LABORATORIES LIMITED's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
